FOUND: Anavex | Mind Blowing Facts

Anavex Life Sciences Stock Is Deeply Oversold. Should You Buy the Dip?

Anavex shares crash as the EMA indicates it won’t issue a positive opinion on its candidate Alzheimer’s drug. Here’s why long-term investors may still consider loading up on AVXL stock today.

Barchart · Mar 26

Short-Squeeze Target Anavex Life Sciences Gains Traction

Anavex Life Sciences stock market is set up for a short squeeze that could begin in early 2025 and increase the price by 400% or more.

MarketBeat · Dec 26, 2024

Anavex Life Sciences Says Rett Syndrome Trial Meets Primary & Secondary Goals

Anavex Life Sciences Corp (NASDAQ: AVXL) reported topline data from the Phase 3 AVATAR trial of ANAVEX2-73 (blarcamesine) in adult female patients with Rett syndrome.

Benzinga · Feb 1, 2022